Brian M. Slomovitz

3 weeks ago | ajmc.com | Brooke McCormick |Brian M. Slomovitz

In the second part of an interview with The American Journal of Managed Care®, Brian Slomovitz, MD, an investigator on the phase 3 ROSELLA trial (NCT05257408), discusses how the combination of relacorilant plus nab-paclitaxel (Abraxane) compares with other available treatment options for patients with platinum-resistant ovarian cancer. He also underscores the importance of the ROSELLA trial's global scope.

3 weeks ago | ajmc.com | Brooke McCormick |Brian M. Slomovitz

Relacorilant combined with nab-paclitaxel (Abraxane) significantly improved progression-free survival and prolonged overall survival in patients with platinum-resistant ovarian cancer compared with nab-paclitaxel alone, according to results from the phase 3 ROSELLA trial (NCT05257408) shared Monday in a late-breaking oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.